Europe Approves Its First Weight-Loss Pill: Oral Semaglutide Gets the Green Light

Weight management just got simpler in Europe. The European Commission has approved a once-daily tablet form of semaglutide, the same ingredient found in Ozempic and Wegovy, for adults with obesity or excess weight. It’s the first oral option of its kind on the continent. As a result, it could change how people think about these treatments altogether.

Until now, anyone in Europe wanting a GLP-1 medication for weight loss had to rely on weekly injections. That’s no small barrier. Some people dislike needles. Others struggle with storing and administering injectable drugs. A pill removes a lot of that friction, since patients simply take it each morning.

Novo Nordisk developed the new 25 mg tablet over several years. First, the European Medicines Agency’s key scientific committee gave it a positive opinion. Then the European Commission granted formal authorization. It’s a milestone moment, though not exactly a surprise, given how the clinical trial data has looked so far.

So who actually qualifies for this treatment? The approval covers adults with a body mass index of 30 or higher, the clinical threshold for obesity. It also extends to people who are overweight, meaning a BMI of 27 or above. However, they must also have a related health issue, such as high blood pressure, type 2 diabetes, or unhealthy cholesterol levels. In short, doctors won’t prescribe this as a casual weight-loss aid. Instead, they’ll reserve it for people whose weight already threatens their health.

The approval rests on solid data. Researchers ran a study called Oasis 4, following 307 adults with obesity or overweight status for 64 weeks. That’s over a year of tracking real outcomes, not just short-term results. Participants took the pill daily and paired it with a reduced-calorie diet and regular exercise.

The results stood out. On average, participants lost 17 percent of their body weight. Meanwhile, the placebo group lost less than 3 percent, so the gap speaks for itself. Interestingly, about a third of participants responded especially well early on. These “early responders” lost roughly 22 percent of their body weight by the study’s end.

A separate analysis adds useful context here. Researchers presented this analysis, called Orion, at the European Congress on Obesity. It compared the oral tablet against other treatments still in development. Notably, the tablet performed about as well as injectable semaglutide already on the market. It also appeared better tolerated than some rival oral drugs, since fewer participants quit treatment due to side effects.

This tablet didn’t appear out of nowhere. A larger clinical trial program called OASIS tested both 25 mg and 50 mg doses in roughly 1,300 adults. All of them had obesity or overweight status combined with a health complication. Mechanically, semaglutide mimics a hormone called GLP-1, which regulates appetite and slows digestion. As a result, patients feel fuller for longer.

The American market has already gone through a similar shift. The FDA approved oral semaglutide for weight loss in late 2025. A few months later, in April 2026, it cleared orforglipron, a newer non-peptide oral GLP-1 drug. Europe’s approval followed on July 16, 2026. Meanwhile, orforglipron is still moving through Europe’s approval process.

Both semaglutide and similar drugs remain prescription-only, and for good reason. These are powerful medications that require medical supervision. Doctors won’t hand them out casually. What remains unclear is how pricing and insurance coverage will play out across different European countries, and what the out-of-pocket cost might look like for patients. Often, that’s where the real bottleneck happens, regardless of how promising a drug looks in trials.

For now, obesity treatment in Europe has entered its oral era. Patients and doctors may choose the pill over the injection based on convenience, cost, and personal preference. Either way, the option finally exists.